In two phase 3 trials (evoke, evoke+) of 3808 participants with early amyloid-confirmed Alzheimer's disease, oral semaglutide did not slow progression vs placebo: CDR-SB change at week 104 differed by -0.08 (p=0.57) and 0.10 (p=0.46).
RCTn = 3,808
Cummings et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials